CytoGenix Announces Completion of synDNA™ Production Module Prototype
News Dec 26, 2005
CytoGenix, Inc. has announced that the prototype version of the synDNA™ production module was completed on schedule.
The device was designed for the commercial production of cell-free DNA by the leading international biopharmaceutical plant design, engineering and construction firm of Alfa Laval Biokinetics, Philadelphia, Pennsylvania.
It was tested by Alfa Laval engineers and CytoGenix senior scientists. The final version will be mounted on a stainless steel cart and have the capacity to produce up to 10 grams of high-purity DNA in 24 hours.
Kurt Berens, CytoGenix, Inc. Vice President of Product Development, commented, "This is an important step in our overall plan to construct a cGMP manufacturing facility."
"We plan to install several synDNA™ production modules to meet the growing demand for clinical-grade DNA internally and from customers."
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE